Keryx Biopharmaceuticals (KERX) Given Average Recommendation of “Hold” by Brokerages
Shares of Keryx Biopharmaceuticals (NASDAQ:KERX) have been given a consensus rating of “Hold” by the eight brokerages that are covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, six have given a hold rating and one has given a buy rating to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $7.00.
A number of research analysts recently commented on KERX shares. ValuEngine downgraded Keryx Biopharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, September 21st. Zacks Investment Research raised Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, October 16th. Finally, Stifel Nicolaus reduced their target price on Keryx Biopharmaceuticals from $7.00 to $5.00 and set a “hold” rating on the stock in a report on Wednesday, November 8th.
Several institutional investors have recently made changes to their positions in the company. Westpac Banking Corp acquired a new stake in Keryx Biopharmaceuticals in the 2nd quarter valued at approximately $390,000. TIAA CREF Investment Management LLC increased its position in shares of Keryx Biopharmaceuticals by 3.6% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 220,336 shares of the biopharmaceutical company’s stock valued at $1,593,000 after purchasing an additional 7,576 shares during the period. Gotham Asset Management LLC acquired a new position in shares of Keryx Biopharmaceuticals during the 2nd quarter valued at $402,000. Schwab Charles Investment Management Inc. increased its position in shares of Keryx Biopharmaceuticals by 1.0% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 441,106 shares of the biopharmaceutical company’s stock valued at $3,190,000 after purchasing an additional 4,388 shares during the period. Finally, Vanguard Group Inc. increased its position in shares of Keryx Biopharmaceuticals by 5.1% during the 2nd quarter. Vanguard Group Inc. now owns 7,198,269 shares of the biopharmaceutical company’s stock valued at $52,043,000 after purchasing an additional 349,521 shares during the period. Institutional investors and hedge funds own 64.82% of the company’s stock.
Keryx Biopharmaceuticals (NASDAQ:KERX) last posted its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.03). The company had revenue of $15.00 million during the quarter, compared to analyst estimates of $18.88 million. Keryx Biopharmaceuticals had a negative net margin of 323.92% and a negative return on equity of 10,954.62%. Keryx Biopharmaceuticals’s quarterly revenue was up 138.1% compared to the same quarter last year. During the same quarter last year, the business posted ($0.39) EPS. research analysts expect that Keryx Biopharmaceuticals will post -1.36 EPS for the current fiscal year.
Keryx Biopharmaceuticals Company Profile
Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.
Receive News & Ratings for Keryx Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.